{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vande Casteele N"],"funding":["Warner Chilcott US, LLC, an indirect subsidiary of Allergan plc","American Gastroenterological Association"],"pagination":["1141-1149"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9328660"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["87(3)"],"pubmed_abstract":["<h4>Aims</h4>Mesalamine is the first-line therapy for treating mild-to-moderate ulcerative colitis. Multiple mesalamine formulations are available, with similar safety and efficacy profiles. Mesalamine is commonly administered as divided dosing, although once-daily dosing may provide benefits for patients. We evaluated the pharmacokinetics of three dosing regimens of two oral delayed-release mesalamine formulations in healthy adult volunteers.<h4>Methods</h4>A randomised, open-label, parallel-group study of mesalamine pharmacokinetics following Lialda 2 × 1.2 g once daily (QD) (dose A), Asacol 6 × 400 mg QD (dose B), or Asacol 2 × 400 mg three times daily (TID) (dose C) over 7 days. Assessments included 5-aminosalicylic acid (5-ASA) and N-acetyl 5-aminosalicylic acid (N-Ac-5-ASA, primary m"],"journal":["British journal of clinical pharmacology"],"pubmed_title":["Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study."],"pmcid":["PMC9328660"],"funding_grant_id":["Research Scholar Award"],"pubmed_authors":["McNamee B","Vande Casteele N","Jakate A","Sandborn WJ"],"additional_accession":[]},"is_claimable":false,"name":"Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.","description":"<h4>Aims</h4>Mesalamine is the first-line therapy for treating mild-to-moderate ulcerative colitis. Multiple mesalamine formulations are available, with similar safety and efficacy profiles. Mesalamine is commonly administered as divided dosing, although once-daily dosing may provide benefits for patients. We evaluated the pharmacokinetics of three dosing regimens of two oral delayed-release mesalamine formulations in healthy adult volunteers.<h4>Methods</h4>A randomised, open-label, parallel-group study of mesalamine pharmacokinetics following Lialda 2 × 1.2 g once daily (QD) (dose A), Asacol 6 × 400 mg QD (dose B), or Asacol 2 × 400 mg three times daily (TID) (dose C) over 7 days. Assessments included 5-aminosalicylic acid (5-ASA) and N-acetyl 5-aminosalicylic acid (N-Ac-5-ASA, primary m","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-09T14:15:58.85Z","creation":"2025-04-19T06:03:31.998Z"},"accession":"S-EPMC9328660","cross_references":{"pubmed":["32671846"],"doi":["10.1111/bcp.14479"]}}